As Merck looks for growth opportunities ahead of Keytruda’s tumble over the patent cliff, the company’s future now looks a ...

While the company’s sales outlook was otherwise rosy, Merck took sales hits on Gardisil, Proquad, Varivax and Vaxneuvance.

Sales of the drug, which comprised nearly half of Merck’s sales last year, totaling $29.5 billion, are expected to peak ...

Merck (MRK) delivered annual earnings growth of 19.4%, outpacing its own 5-year average growth rate of 13.4%. Profit margins ...

Some four years into its run as an independent women’s health outfit, Organon is parting ways with its first CEO after an ...

Merck said its narrowed profit guidance reflects several new items, including "lower estimated costs related to the impact of ...

Merck boosts its full-year outlook as third-quarter earnings top estimates following strong demand for its blockbuster cancer ...

Merck, a leading science and technology company, has entered into a partnership with Promega Corporation, a global life ...

Compared to its lackluster second quarter performance, Merck rallied somewhat in the third quarter of 2025. Revenue and ...

Organon said on Monday CEO Kevin Ali will resign from his role, after an internal investigation into sales of its Nexplanon ...

Organon appoints Joseph Morrissey as interim CEO after an investigation into Nexplanon sales practices and the exit of CEO ...